Genkyotex : Visibilité financière jusqu’à début 2020 – Résultats de phase 2 au T2 2019e
>10.2 M€ à fin 2018 – visibilité financière début 2020 - Genkyotex publiait hier après marché sa position de trésorerie à fin décembre 2018 et en a profité pour faire un point sur les avancées de sa phase 2 dans la cholangite biliaire primitive (CBP). La trésorerie ressort à 10.2 M€ à fin décembre 2018 offrant ainsi une visibilité financièrejusqu’au début de l’année 2020. A noter que le principal poste de dépense de la société est la phase 2 de son GKT831 dans la...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.